# Pemirolast in Allergen Challenge (PEMAG)

> **NCT03119714** · PHASE2 · TERMINATED · sponsor: **Karolinska University Hospital** · enrollment: 1 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** Pemirolast
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03119714
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to results from other studies regarding efficacy of pemirolast
- **Last updated:** 2019-05-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03119714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03119714, "Pemirolast in Allergen Challenge (PEMAG)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03119714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*